Cargando…

CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.

Sixty-three patients with extensive-stage small-cell lung cancer were randomized to receive either cyclophosphamide, vincristine, doxorubicin and etoposide (CODE) alone or CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF). rhG-CSF administration in support of CODE chemother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukuoka, M., Masuda, N., Negoro, S., Matsui, K., Yana, T., Kudoh, S., Kusunoki, Y., Takada, M., Kawahara, M., Ogawara, M., Kodama, N., Kubota, K., Furuse, K.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group\|1 1997
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063260/ https://www.ncbi.nlm.nih.gov/pubmed/9010043

Ejemplares similares

Determinants of Myelosuppression in the Treatment of Non‐small Cell Lung Cancer with Cisplatin‐containing Chemotherapy
por: Matsui, Kaoru, et al.
Publicado: (1996)

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.
por: Matsui, K., et al.
Publicado: (1998)

Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation.
por: Kawahara, M., et al.
Publicado: (1998)

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
por: Kudoh, Shinzoh, et al.
Publicado: (1995)

A pilot study of concurrent whole-brain radiotherapy and chemotherapy combined with cisplatin, vindesine and mitomycin in non-small-cell lung cancer with brain metastasis.
por: Furuse, K., et al.
Publicado: (1997)

Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.
por: Yokose, N., et al.
Publicado: (1998)

Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer
por: Takeda, K, et al.
Publicado: (1999)

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
por: Masuda, N., et al.
Publicado: (1993)

Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)
por: Yamamoto, N, et al.
Publicado: (2004)

Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts
por: Kudoh, Shinzoh, et al.
Publicado: (1993)

Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.
por: Matsui, K., et al.
Publicado: (1996)

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B(12) in Japanese patients with solid tumours
por: Nakagawa, K, et al.
Publicado: (2006)

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
por: Negoro, S, et al.
Publicado: (2003)

Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay.
por: Takada, M., et al.
Publicado: (1995)

Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
por: Takada, M., et al.
Publicado: (1996)

Granulocyte Colony-Stimulating Factor-Producing Bladder Cancer
por: Morinaga, Ryota, et al.
Publicado: (2019)

Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991-96.
por: Niitsu, N., et al.
Publicado: (1997)

In vitro Colony Forming Cells and Colony Stimulating Factor in Chronic Granulocytic Leukaemia
por: Goldman, J. M., et al.
Publicado: (1974)

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
por: Kawahara, M, et al.
Publicado: (2001)

Immunohistochemical analysis of Bcl-2 protein in early squamous cell carcinoma of the bronchus treated with photodynamic therapy
por: Kawaguchi, T, et al.
Publicado: (2000)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Use of granulocyte colony-stimulating factor in patients with chemotherapy-induced neutropaenia
por: Shokane, Lucky L., et al.
Publicado: (2023)

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
por: Bronchud, M. H., et al.
Publicado: (1987)

Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue.
por: Masuda, N., et al.
Publicado: (1998)

Autonomous production of granulocyte-colony stimulating factor in tumour xenografts associated with leukocytosis.
por: Katoh, Y., et al.
Publicado: (1993)

Phase I–II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer
por: Tsuda, H, et al.
Publicado: (2004)

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
por: Yamada, M, et al.
Publicado: (2002)

Comparison of the effects of pegylated granulocyte-colony stimulating factor and granulocyte-colony stimulating factor on cytopenia induced by dose-dense chemotherapy in breast cancer patients
por: Ashrafi, Farzaneh, et al.
Publicado: (2018)

Recurrent Granulocyte Colony-Stimulating Factor-Induced Aortitis After Pegfilgrastim Administration
por: Kawahara, Hiroshi, et al.
Publicado: (2020)

In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients.
por: Bronchud, M. H., et al.
Publicado: (1988)

Granulocyte, granulocyte–macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells
por: Pei, X-H, et al.
Publicado: (1999)

Granulocyte colony‐stimulating factor associated arteritis in a patient with castration‐resistant prostate cancer
por: Nitta, Satoshi, et al.
Publicado: (2021)

Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level
por: Baig, Hassam, et al.
Publicado: (2018)

Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice
por: Krzemieniecki, K., et al.
Publicado: (2013)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

Psoriasiform eruption triggered by recombinant granulocyte-macrophage colony stimulating factor (rGM-CSF) and exacerbated by granulocyte colony stimulating factor (rG-CSF) in a patient with breast cancer.
por: Cho, S. G., et al.
Publicado: (1998)

Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy
por: Gawade, Prasad L., et al.
Publicado: (2020)

Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis
por: Katano, Mitsuo, et al.
Publicado: (1995)

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
por: Tamura, K, et al.
Publicado: (2008)

Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer
por: Masuda, Noriyuki, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2irp7jt2bgao5rbp57nlatnv2l